ARTHEx Biotech’s Post

Kesmalea is proud to welcome Rob Johnson as CEO! Fresh from leading Adrestia Therapeutics (acquired by Insmed, Inc.), Rob will take the helm as we build a pipeline of oral, CNS penetrant targeted protein degrader therapeutics. These attributes are difficult to achieve for most large degraders today, but Kesmalea's SELFTAC platform was created to transform large degraders into small molecules through a self-assembling linker technology. By combining the favorable attributes of small molecules with the versatility and power of protein degradation, our goal is to bring a new class of SELFTAC degraders to patients. Read more in our press release: https://lnkd.in/e9ieuamh #biotech #CEO #therapeutics #PROTAC

🎉 At Tebubio, we’re excited to announce the expansion of our Lipid Nanoparticle (LNP) encapsulation services, now powered by the cutting-edge TAMARA platform from Inside Therapeutics (InsideTx) With this advanced capability, we are supporting researchers and innovators in unlocking the full potential of RNA-based therapeutics through precise encapsulation and efficient delivery systems. ➡️ The acquisition of this instrument marks a significant milestone, enabling us to increase our capacity from µg scale to a few mg while maintaining short turnaround times. In just a couple of weeks, we can optimize the encapsulation of your mRNA and deliver LNPs directly to your lab. Furthermore, this recent development in our delivery platform is reinforced by the expertise of our suppliers and partners, granting us access to an extensive range of lipids. This allows us to tailor your LNPs to meet your specific needs. 🔎 Discover more about Tebubio’s services here: https://lnkd.in/ee9rSaP6 #LipidNanoparticles #RNAtherapeutics #BiotechInnovation #InsideTherapeutics #Tebubio [WeAreTebubio]

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

We hope you'll join us in Boston, Sept. 17-19, at the mRNA Process Development & Manufacturing Summit, part of the World RNA Series! Don't miss our speaker session, Sept. 19 at 11:45am ET. Brenda Clemente, Associate Director and Head of Formulation and Process Development with Arcturus Therapeutics, will discuss new data around the development and qualification of small-scale #mRNA lipid nanoparticle manufacture. Discussion will include how to establish and optimize critical operating parameters from DOE study results. Learn more: https://lnkd.in/eE6fh_kY #processdevelopment #mRNAtherapeutics #WorldRNA

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

Stop by and check out Vector Labs newest and greatest tomorrow at The Cove! Let’s talk about our new dPEG Linker platform for BioDesign of Bioconjugate Therapeutics. #vectorlabs #ADCs #dPEG #BioDesign

💡Discover more about this use case of GOLD and its integration within Dassault Systèmes BIOVIA therapeutics design software Discovery Studio. In this work, the scientists used the CCDC’s protein-ligand docking software GOLD to perform docking studies on selective ligands for a receptor involved in glutamate regulation. 🔗https://lnkd.in/eiUXps2Y #Docking

ProcartaPlex assays by ThermoFisher Scientific have helped researchers unravel LNP reactogenicity mechanisms. In fact, a recent study used ProcartaPlex assays by @ThermoFisherScientific to uncover the role of the TLR4-MyD88 axis in LNP-induced reactogenicity, providing insights that may contribute to developing safer mRNA therapeutics. Learn more in the October edition of our xMAP® Resource Round-Up newsletter, now available in your inbox. Subscribe to our free #xMAP newsletter for monthly updates on all things xMAP: https://hubs.ly/Q02XdlL20 #biotech #labinnovation

Struggling to ensure access to nucleic acid medicines worldwide? 🌍 We understand the importance of reaching every patient in need, regardless of location or resources. Our state-of-the-art facilities and specialized expertise in nucleosides, nucleotides, and phosphoramidites put us at the forefront of innovation in RNA therapeutics. From incremental improvements to transformative advances, we're driving change in global healthcare through innovative manufacturing solutions. Are you seeking a trusted global partner in nucleic acid innovation for your next project? Find out how we can support you here. 👇 https://loom.ly/SUL1QXA #Pharma #CDMO #NucleicAcid #Biotech